Found: 6
Select item for more details and to access through your institution.
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.
- Published in:
- Cell Death & Disease, 2018, v. 9, n. 11, p. 1, doi. 10.1038/s41419-018-1143-3
- By:
- Publication type:
- Article
A Case of Dystiophic Epidermolysis Bullosa Improved with Etanercept for Concomitant Psoriatic Arthritis.
- Published in:
- 2010
- By:
- Publication type:
- Case Study
Toxic epidermal necrolysis successfully treated with etanercept.
- Published in:
- Journal of Dermatology, 2009, v. 36, n. 3, p. 150, doi. 10.1111/j.1346-8138.2009.00616.x
- By:
- Publication type:
- Article
Biological drugs targeting the immune response in the therapy of psoriasis.
- Published in:
- Biologics: Targets & Therapy, 2008, v. 2, n. 4, p. 687
- By:
- Publication type:
- Article
Papular Neutrophilic Dermatosis and Erythema Elevatum Diutinum Following Erythropoietin Therapy in a Patient with Myelodysplastic Syndrome.
- Published in:
- Acta Dermato-Venereologica, 2003, v. 83, n. 5, p. 358
- By:
- Publication type:
- Article
Subacute Cutaneous Lupus Erythematosus Induced by Nifedipine.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2003, v. 7, n. 3, p. 243, doi. 10.1007/s10227-002-0122-5
- By:
- Publication type:
- Article